Aeolus Pharmaceuticals (AOLS)

[Sheep]

Aeolus Files International Patent Application for New Patent on AEOL 10150
http://finance.yahoo.com/news/aeolus-files-international-patent-application-133000916.html
MISSION VIEJO, CA--(Marketwired - December 03, 2014) - Aeolus Pharmaceuticals, Inc. (AOLS)

Filing covers synthesis, formulation and pharmaceutical composition
Could significantly increase term of patent protection for AEOL 10150

Aeolus Pharmaceuticals, Inc. (AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today that it has filed an international patent application under the Patent Cooperation Treaty (PCT) with the United States Receiving Office (US/RO) thereby preserving the right to seek patent protection in all PCT contracting countries for new patents covering new inventions resulting from research and development on its lead compound, AEOL 10150. Patents resulting from this application, if granted, would cover novel synthesis routes, crystal forms and pharmaceutical compositions of AEOL-10150 and related porphyrin compounds. The intellectual property underlying this new patent filing is a direct result of work performed under Aeolus' contract with the Biomedical Advanced Research and Development Authority ("BARDA"). The five year, $118 million, cost-plus contract, awarded in February 2011, includes funding for the development of large-scale, Good Manufacturing Practice production capacity for AEOL 10150.

"These new patents, if granted, would substantially increase the life of the patent protection surrounding AEOL 10150 throughout the world," stated John McManus, Chief Executive Officer of Aeolus Pharmaceuticals, Inc. "Extended patent life would open up new potential strategic options for our AEOL 10150 radiation therapy and lung fibrosis development programs. The work that led to this filing is an excellent example of the value that BARDA brings as a partner in advanced drug development."